About Matthew O'Connor
Form D filings for Cyclarity Therapeutics from 2019 to 2024 list Matthew O'Connor as co-chief executive officer and director.
Matthew O'Connor first appears on SEC filings in 2019.
Experience
This experience comes from SEC filings. The years are when the filings name Matthew O'Connor in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Matthew O'Connor works with at each company, as listed on that company's latest Form D.
Cyclarity Therapeutics, Inc. · Form D, Dec 30, 2024
MK
Michael Kope
Executive officer and director